Qualifications and history:
Since 2013: Deputy Managing Director, NMI
2008 - 2014 Director Strategic Alliances, EDI GmbH, Reutlingen (part time)
2000 - 2017 Head of Biochemistry Department, NMI
1998 - 2000 Research Assistant, NMI
1994 – 1998: Postdoctoral research, Dept. of Cell Biology, Max Planck Institute for Developmental Biology, Tübingen
1994: Ph.D. degree (Dr. rer. nat), Dept. of Cell Biology, Max Planck Institute for Developmental Biology, Tübingen (under Prof. P. Hausen; Topic: "Integrin-α5 during early embroygenesis of Xenopus laevis"
04–08 1988: Molecular biology practical, Biochemistry Dept., the Brandeis University“(under Prof. Andrew Szent-Györgyi), Waltham, Massachusetts, USA
1984 – 1990: Study of Biochemistry, University of Tübingen
Dr. Joos is a member of the editorial board of "Drug Discovery Today", "Proteomics" and "Expert Review of Proteomics".
He is a member of the Scientific Advisory Board of the Plasma Proteomics Institute in Washington, DC, USA and a member of the Scientific Advisory Board of Myriad RBM Inc. in Austin, Texas, USA.
Dr. Joos is the author of >100 scientific papers. He is recognized worldwide as an expert and opinion leader in the technology field of biomarkers and their clinical applications and basic research.
Dr. Joos is co-founder of SIGNATOPE GmbH, Reutlingen. SIGNATOPE develops innovative protein tests with which biomarkers for organ damage and drug interactions can be detected in all pharma-relevant species.